Keywords
How to Cite
Abstract
The ELN2017 stratification has proved useful in predicting the outcome for Acute Myeloid Leukemia (AML). However, some molecular determinations detailed are limited in use in our media and the karyotype remains an important factor regarding therapy. Our aim was to evaluate the predictive capacity of different cytogenetic and molecular findings on the outcome of patients with AML.
Data was informative in 592 patients (pt) (from a retrospective cohort of 688pt, diagnosed in 11 Argentine centers between Jan/13-Jun/19). The overall survival (OS) concerning genetic data was different: t(15;17), 77pt, not reached (NR); CBF rearrangements, 65pt, NR; normal karyotype, 254pt, 13m, and abnormal karyotype, 196pt, 8m; p<0.001.
Regarding normal karyotype, combined data according to the ELN2010 showed differences in the outcome: NPM1+/FLT3-, 26pt, NR; NPM1-/FLT3-, 102pt, 14m; NPM1-/FLT3+, 21pt, 9m; NPM1+/FLT3+, 12pt, 7m; p=0.025 (CEPBA available 62pt, no evaluable).
Adverse karyotypes were heterogeneously distributed among 9 systems: 47% CECOG-SWOG-MDACC to 99% Keating-classification, and 104 (55%) with changes related to Myelodysplastic Syndromes. The CECOG-SWOG-MDACC showed superiority to differentiate between intermediate vs adverse for OS (10 vs 6m, p=0.004; HR1.6, p=0.007, Cox’s regression) and, in the limit, for those who undergone hematopoietic stem cell transplantation (HSCT) (NA vs 15m, p=0.033; HR 2.5, p=0.053). Regarding hypomethylating agents (41pt) as first line therapy none was useful to differentiate OS (9m), complete remission (CR) or best response. When chemotherapy was evaluated, the CECOG-SWOG-MDACC and ELN2010 were similar censoring (13 vs 8m, p=0.023 and 15 vs 8m, p=0.018) or not censoring at HSCT (14 vs 8m, p=0.009, and 16 vs 8m, p=0.005). However, only the first one made a difference in CR rates (73% vs 52%, p=0.023), with a tendency for any therapy (p=0.057).
Finally, all findings were compared, selecting t(15;17) as reference and applying the CECOG-SWOG-MDACC: CBF HR1.6 p=0.184; normal karyotype NPM1+/FLT3- HR2.3, p=0.057; normal karyotype NPM1-/FLT3- HR4.2, p<0.001; intermediate HR5.6, p<0.001; normal karyotype NPM1-/FLT3+ HR6.1, p<0.001; normal karyotype NPM1+/FLT3+ HR9.9, p<0.001, and adverse HR8.2, p<0.001. These HRs increased when excluding HSCT, especially for FLT3+.
Our results are in agreement with the favorable outcome of t(15;17), CBF rearrangement and NPM1+/FLT3- in those with normal karyotype, whereas FLT3+ was an adverse finding. Complex karyotypes, -5 and -7, according CECOG-SWOG-MDACC, were associated with shorter OS and lower CR. However, when rearr3q, 5q-, 11q23v and 17p- were also included, according to ELN2010, they account for a shorter OS in those treated with chemotherapy.
References
2. Harada Y, Nagata Y, Kihara R, y col. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res 2018;66:20-7.
3. Döhner H, Estey EH, Amadori S, y col. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
4. Byrd JC, Mrózek K, Dodge RK y col. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
5. Walter RB, Kantarjian HM, Huang X , y col. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010;28:1766-71.
6. Stelljes M, Beelen DW, Braess J, y col. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica 2011;96:972-9.
7. Büchner T, Berdel WE, Schoch C y col. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24:2480-9.
8. Grimwade D, Hills RK, Moorman AV, y col. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354-65.
9. Oosterveld M, Suciu S, Muus P, y col. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. Ann Hematol 2015; 94:23-34.
10. Greenberg P, Cox C, LeBeau M, y col. International International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
11. Keating S, Suciu S, de Witte T, y col. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003; 17: 60-7
12. Swerdlow SH, Campo E, Harris NL, y col, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2017 Revised 4th Edition, Lyon, IARC press, 2017.
13. Murphy KM, Levis M, Hafez MJ, y col. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003; 5: 96-102.
14. Kiyoi H, Naoe T, Nakano Y, y col. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-80.
15. Yamamoto Y, Kiyoi H, Nakano Y, y col. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97:2434-9.
16. Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, Gianni L, Postorino M, Federici G, Amadori S, Lo Coco F. An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn. 2008;10:212–216.
17. Calvo KL, Ojeda MJ, Ammatuna E y col. Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis. Eur J Haematol 2008; 82: 69–72.
18. Mrozek K, Marcucci G, Paschka P, y col. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431-48.
19. Stone RM. Mandrekar SJ, Sanford BL, y col. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017; 377: 454-64.
20. Haferlach C, Alpermann T, Schnittger S, y col. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012; 119: 2122-5.
21. Breems DA, van Putten WL, de Greef GE, y col. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-7.
22. Middeke JM, Beelen D, Stadler M y col. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and-5/5q-. Blood 2012; 120: 2521-8.
23. Gonzalez J, Villaverde N, Kantor G y col. Diagnóstico y tratamiento de las Leucemias Mieloides Agudas (LMA) según el tipo de sistema de salud. Hematología 2019; 23 (S2): 69.
24. Gimenez Conca A, Basquiera A, Perusini A y col. Enfermedad residual medible post induccion por citometria de flujo en Leucemia Mieloide Aguda no promielocítica. Estudio colaborativo. Hematología 2019; 23 (S2): 34.
25. Mela Osorio M, Belli C, Ferrari L y col. Impacto de la respuesta a agentes hipometilantes o quimioterapia intensiva en la sobrevida de pacientes con LMA mayores de 65 años. Hematología 2019; 23 (S2): 34.
26. Belli CB, Dick H, Giménez Conca AD. Influencia de la progresión leucémica en el pronóstico de los pacientes con síndromes mielodisplásicos y experiencia nacional en leucemias mieloides agudas secundarias. Hematología 2019; 23 (N Extraordinario): 161-70.
27. Perusini A, Basquiera A, Gimenez Conca A y col. Mortalidad temprana en Leucemia Mieloide Aguda: Experiencia Multicéntrica. Hematología 2019; 23 (S2): 49.
28. Gimenez Conca A, Perusini A, Basquiera A y col. Análisis de supervivencia global en Leucemias Agudas no promielocíticas. Datos de una base colaborativa. Hematología 2019; 23 (S2): 49.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar